European stocks look like newly good investments amid Trump's tariff war and US economic unpredictabilities. European defense stocks are particularly appealing.

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...

Wearable and implantable biosensors that can accurately detect biological molecules in a non- or minimally invasive manner ...

Scientists have identified the Plvap gene as a key regulator of metabolism during fasting. Disabling it in mice prevented the ...

But how do these microbial communities work? And can we harness their power to make agriculture more sustainable? These ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...